Vericiguat

Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and heart failure. It is taken by mouth.
Common side effects include low blood pressure and low red cell count (anemia).
Vericiguat is a soluble guanylate cyclase (sGC) stimulator. It was approved for medical use in the United States in January 2021.
Medical uses.
Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Adverse effects.
Vericiguat causes harm to the unborn baby and should not be given to pregnant women.
History.
The U.S. Food and Drug Administration (FDA) approved vericiguat based on evidence from a clinical trial (NCT02861534) which consisted of 5,050 participants aged 23 to 98 years old with worsening heart failure. The trial was conducted at 694 sites in 42 countries in Europe, Asia, North and South America. The trial enrolled participants with symptoms of worsening heart failure. Participants were randomly assigned to receive vericiguat or a placebo pill once a day. Neither the participants nor the health care professionals knew if the participants were given vericiguat or placebo pill until after the trial was complete.